Genes expressed in prostate cancer
AssigneeNone recorded
InventorsMary Faris, Cecelia I. Pearson
Life of this patent
Estimating the term…
Abstract
The present invention relates to a combination comprising a plurality of cDNAs which are differentially expressed in prostate cancer and which may be used in their entirety or in part as to diagnose, to stage to treat or to monitor the progression or treatment of prostate cancer.
Drawings
Claims20
A combination comprising a plurality of cDNAs, wherein the cDNAs are selected from SEQ ID NOs:1-501 and the complements of SEQ ID NOs:1-501.
An isolated cDNA selected from SEQ ID NOs:
- 14, 26, 40, 52, 55, 60, 65, 68, 73, 79, 82, 85, 92, 110, 112, 114, 115, 117, 122, 125, 126, 130, 136, 137, 139, 141, 143, 144, 145, 146, 147, 160, 164, 166, 167, 168, 190, 191, 194, 195, 199, 201, 204, 211, 212, 222, 224, 226, 229, 233, 234, 240, 243, 245, 248, 250, 253, 254, 259, 264, 268, 269, 270, 272, 276, 278, 279, 281, 282, 284, 285, 286, 293, 296, 297, 299, 300, 301, 362, 306, 308, 312, 313, 314, 317, 319, 321, 321, 322, 322, 323, 324, 325, 326, 330, 331, 332, 334, 336, 337, 338, 339, 340, 342, 346, 353, 355, 357, 361, 365, 366, 371, 372, 376, 380, 383, 385, 386, 387, 390, 399, 400, 402, 405, 406, 408, 409, 410, 412, 413, 417, 418, 419, 420, 422, 422, 424, 426, 438, 444, 445, 453, 456, 460, 461, 471, 479, 480, 487, 490, 492, 495, 496, and 497 and the complements thereof.
Dependencies are inferred from the claim text.